Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future

Rajni Sinha1, Loretta J Nastoupil2, Christopher R Flowers11Department of Hematology/Medical Oncology, Winship Cancer Institute, 2Department of Hematology and Oncology, Emory University, Atlanta, GA, USAAbstract: Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Wes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Flowers CR, Nastoupil LJ, Sinha R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/d795dab86a484013bc53244922df03a8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d795dab86a484013bc53244922df03a8
record_format	dspace
spelling	oai:doaj.org-article:d795dab86a484013bc53244922df03a82021-12-02T06:32:06ZTreatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future1179-9889https://doaj.org/article/d795dab86a484013bc53244922df03a82012-04-01T00:00:00Zhttp://www.dovepress.com/treatment-strategies-for-patients-with-diffuse-large-b-cell-lymphoma-p-a9731https://doaj.org/toc/1179-9889Rajni Sinha1, Loretta J Nastoupil2, Christopher R Flowers11Department of Hematology/Medical Oncology, Winship Cancer Institute, 2Department of Hematology and Oncology, Emory University, Atlanta, GA, USAAbstract: Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. DLBCLs are clinically, biologically, and pathologically heterogeneous with biologically distinct subtypes that have different expected treatment outcomes. The addition of rituximab to combination chemotherapy has improved outcomes for all patients with DLBCL and can cure the disease in certain individuals. Relapsed DLBCL is generally managed with salvage chemoimmunotherapy followed by high-dose therapy and autologous stem cell transplantation, which can cure additional patients. However, outcomes for patients who relapse early after upfront rituximab and chemotherapy are poor. Novel therapies and strategies are desperately needed for these patients and several emerging treatments hold promise for improving DLBCL treatment outcomes.Keywords: non-Hodgkin&#39;s lymphoma, diffuse large B-cell lymphoma, lymphoma, chemoimmunotherapy, rituximab, treatmentFlowers CRNastoupil LJSinha RDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 87-98 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Flowers CR Nastoupil LJ Sinha R Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
description	Rajni Sinha1, Loretta J Nastoupil2, Christopher R Flowers11Department of Hematology/Medical Oncology, Winship Cancer Institute, 2Department of Hematology and Oncology, Emory University, Atlanta, GA, USAAbstract: Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. DLBCLs are clinically, biologically, and pathologically heterogeneous with biologically distinct subtypes that have different expected treatment outcomes. The addition of rituximab to combination chemotherapy has improved outcomes for all patients with DLBCL and can cure the disease in certain individuals. Relapsed DLBCL is generally managed with salvage chemoimmunotherapy followed by high-dose therapy and autologous stem cell transplantation, which can cure additional patients. However, outcomes for patients who relapse early after upfront rituximab and chemotherapy are poor. Novel therapies and strategies are desperately needed for these patients and several emerging treatments hold promise for improving DLBCL treatment outcomes.Keywords: non-Hodgkin&#39;s lymphoma, diffuse large B-cell lymphoma, lymphoma, chemoimmunotherapy, rituximab, treatment
format	article
author	Flowers CR Nastoupil LJ Sinha R
author_facet	Flowers CR Nastoupil LJ Sinha R
author_sort	Flowers CR
title	Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
title_short	Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
title_full	Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
title_fullStr	Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
title_full_unstemmed	Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future
title_sort	treatment strategies for patients with diffuse large b-cell lymphoma: past, present, and future
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/d795dab86a484013bc53244922df03a8
work_keys_str_mv	AT flowerscr treatmentstrategiesforpatientswithdiffuselargebcelllymphomapastpresentandfuture AT nastoupillj treatmentstrategiesforpatientswithdiffuselargebcelllymphomapastpresentandfuture AT sinhar treatmentstrategiesforpatientswithdiffuselargebcelllymphomapastpresentandfuture
_version_	1718399903359565824

Treatment strategies for patients with diffuse large B-cell lymphoma: past, present, and future

Ejemplares similares